ライフサイエンスコーパス: cilastatin

1 ure who were initially treated with imipenem/cilastatin.

2 thelial cells provided by the megalin ligand cilastatin.

3 buprenorphine (0.05 mg/kg, SC) and imipenem/cilastatin (14 mg/kg, SC) in 1.5 mL of warm saline (40 m

4 id 219 of 270 patients treated with imipenem/cilastatin (81%).

5 Addition of cilastatin, an inhibitor of dehydropeptidase- l (cystein

6 Cilastatin and dexamethasone were complexed to H-Dot nan

7 subjects underwent skin tests with imipenem/cilastatin and meropenem; 130 of them were skin-tested a

8 illin, amoxicillin-clavulanate, and imipenem-cilastatin), and lipopeptides or glycopeptides.

9 ucted to compare clinafloxacin with imipenem/cilastatin as adjuncts in the management of complicated

10 bials at standard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, piperacillin/tazobact

11 Cilastatin complexation conferred proximal tubular epith

12 Blocking DPEP1 with cilastatin, deleting Dpep1, or administering LTD(4) oral

13 The Cilastatin/Dexamethasone/H-Dot nanotherapeutic improved

14 Cilastatin/Dexamethasone/H-Dot nanotherapeutics were fou

15 cin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-abdominal

16 5.5% rate of cross-reactivity with imipenem/cilastatin in subjects with T-cell-mediated hypersensiti

17 Ferroptosis inhibitors, the DPEP1 inhibitor cilastatin, or genetic DPEP1 inactivation reversed the d

18 eracillin/tazobactam, meropenem and imipenem/cilastatin (P-I-M), in the 4 weeks before therapy was as

19 (500 mg every 12 hours), meropenem, imipenem/cilastatin, penicillin G, ampicillin, ampicillin/sulbact

20 the stria vascularis, by binding competitor cilastatin prevented GTTR accumulation in HCs.

21 -avibactam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, and sulbac

22 %) to cefiderocol (FCR), 7 (70%) to imipenem/cilastatin/relebactam (I/R), 3 (30%) to ceftazidime/avib

23 th HABP/VABP were randomized 1:1 to imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg or piperacill

24 all-cause mortality was 15.9% with imipenem/cilastatin/relebactam and 21.3% with piperacillin/tazoba

25 , the MITT population comprised 264 imipenem/cilastatin/relebactam and 267 piperacillin/tazobactam pa

26 , the MITT population comprised 264 imipenem/cilastatin/relebactam and 267 piperacillin/tazobactam pa

27 e events (AEs) occurred in 26.7% of imipenem/cilastatin/relebactam and 32.0% of piperacillin/tazobact

28 We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acquired/vent

29 Imipenem/cilastatin/relebactam is an appropriate treatment option

30 Imipenem/cilastatin/relebactam was noninferior (P < .001) to pipe

31 Furthermore, cilastatin treatment markedly reduced AG-induced HC dege

32 st that utilized intravenous (i.v.) imipenem-cilastatin, which is less expensive than reference stand